90 related articles for article (PubMed ID: 18303964)
1. Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids.
Kirchheiner J; Meineke I; Fuhr U; Rodríguez-Antona C; Lebedeva E; Brockmöller J
Pharmacogenomics; 2008 Mar; 9(3):277-88. PubMed ID: 18303964
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Kirchheiner J; Thomas S; Bauer S; Tomalik-Scharte D; Hering U; Doroshyenko O; Jetter A; Stehle S; Tsahuridu M; Meineke I; Brockmöller J; Fuhr U
Clin Pharmacol Ther; 2006 Dec; 80(6):657-67. PubMed ID: 17178266
[TBL] [Abstract][Full Text] [Related]
3. Genetic markers in the EET metabolic pathway are associated with outcomes in patients with aneurysmal subarachnoid hemorrhage.
Donnelly MK; Conley YP; Crago EA; Ren D; Sherwood PR; Balzer JR; Poloyac SM
J Cereb Blood Flow Metab; 2015 Feb; 35(2):267-76. PubMed ID: 25388680
[TBL] [Abstract][Full Text] [Related]
4. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.
Pedersen RS; Damkier P; Brosen K
Br J Clin Pharmacol; 2006 Dec; 62(6):682-9. PubMed ID: 16856883
[TBL] [Abstract][Full Text] [Related]
5. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
6. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
7. Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population.
Arun Kumar AS; Kumar SS; Umamaheswaran G; Kesavan R; Balachandar J; Adithan C
Pharmacol Rep; 2015 Feb; 67(1):97-101. PubMed ID: 25560582
[TBL] [Abstract][Full Text] [Related]
8. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.
Aquilante CL; Bushman LR; Knutsen SD; Burt LE; Rome LC; Kosmiski LA
Hum Genomics; 2008 Sep; 3(1):7-16. PubMed ID: 19129086
[TBL] [Abstract][Full Text] [Related]
9. Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells.
Suzuki S; Oguro A; Osada-Oka M; Funae Y; Imaoka S
J Pharmacol Sci; 2008 Sep; 108(1):79-88. PubMed ID: 18776712
[TBL] [Abstract][Full Text] [Related]
10. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.
Tomalik-Scharte D; Fuhr U; Hellmich M; Frank D; Doroshyenko O; Jetter A; Stingl JC
Drug Metab Dispos; 2011 May; 39(5):927-32. PubMed ID: 21270106
[TBL] [Abstract][Full Text] [Related]
11. Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure.
Yeo KR; Kenny JR; Rostami-Hodjegan A
Eur J Clin Pharmacol; 2013 Jun; 69(6):1311-20. PubMed ID: 23307233
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel allelic variant of CYP2C8, CYP2C8*11, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo.
Yeo CW; Lee SJ; Lee SS; Bae SK; Kim EY; Shon JH; Rhee BD; Shin JG
Drug Metab Dispos; 2011 Apr; 39(4):711-6. PubMed ID: 21245287
[TBL] [Abstract][Full Text] [Related]
13. Determination of 14,15-epoxyeicosatrienoic acid and 14,15-dihydroxyeicosatrienoic acid by fluoroimmunoassay.
Nithipatikom K; Falck JR; Bhatt RK; Hanke CJ; Campbell WB
Anal Biochem; 1997 Mar; 246(2):253-9. PubMed ID: 9073364
[TBL] [Abstract][Full Text] [Related]
14. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.
Hruska MW; Amico JA; Langaee TY; Ferrell RE; Fitzgerald SM; Frye RF
Br J Clin Pharmacol; 2005 Jan; 59(1):70-9. PubMed ID: 15606443
[TBL] [Abstract][Full Text] [Related]
15. Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs.
Nithipatikom K; DiCamelli RF; Kohler S; Gumina RJ; Falck JR; Campbell WB; Gross GJ
Anal Biochem; 2001 May; 292(1):115-24. PubMed ID: 11319825
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
Cabaleiro T; Román M; Ochoa D; Talegón M; Prieto-Pérez R; Wojnicz A; López-Rodríguez R; Novalbos J; Abad-Santos F
Drug Metab Dispos; 2013 Jan; 41(1):224-9. PubMed ID: 23118328
[TBL] [Abstract][Full Text] [Related]
18. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
Muschler E; Lal J; Jetter A; Rattay A; Zanger U; Zadoyan G; Fuhr U; Kirchheiner J
Basic Clin Pharmacol Toxicol; 2009 Dec; 105(6):374-9. PubMed ID: 19614891
[TBL] [Abstract][Full Text] [Related]
19. Genetic variance in CYP2C8 and increased risk of myocardial infarction.
Rodenburg EM; Visser LE; Danser AH; Hofman A; van Noord C; Witteman JC; Uitterlinden AG; Stricker BH
Pharmacogenet Genomics; 2010 Jul; 20(7):426-34. PubMed ID: 20436375
[TBL] [Abstract][Full Text] [Related]
20. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects.
Kim KA; Park PW; Kim HK; Ha JM; Park JY
J Clin Pharmacol; 2005 Aug; 45(8):941-6. PubMed ID: 16027405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
